Conjunctivitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Conjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions.
Conjunctivitis, commonly known as “pink eye”, refers to inflammation of the conjunctiva, the thin, transparent layer covering the white part of the eye and the inner surface of the eyelids. This condition can be caused by various factors, including infections, allergies, or irritants. Viral conjunctivitis is typically caused by viruses associated with the common cold; it is highly contagious and often spreads through coughing, sneezing, or direct contact with infected eye secretions. It causes redness, watery eyes, and sometimes a gritty feeling. Bacterial conjunctivitis can lead to redness, swelling, a sticky discharge, and crusty eyelids, especially after sleep. It’s also contagious and can spread through direct contact. Allergic conjunctivitis is triggered by allergens such as pollen, dust, or pet dander, and can result in red, itchy, and watery eyes, and is not contagious. Irritant conjunctivitis is caused by irritants such as smoke, chemicals, or foreign objects entering the eye, leading to redness, watering, and discomfort, and is also not contagious.
The Conjunctivitis drugs in development market research report provide comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Conjunctivitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Conjunctivitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 59 molecules, with 59 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Conjunctivitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Conjunctivitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Conjunctivitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Accolade Pharmaceuticals LLCAldeyra Therapeutics Inc
Alexion Pharmaceuticals Inc
ALK-Abello AS
Allakos Inc
Allergy Therapeutics Plc
Amytrx Therapeutics Inc
Bioxytran Inc
Cellics Therapeutics Inc
Chongqing Zhifei Biological Products Co Ltd
Clevexel Pharma SA
Faes Farma SA
Formosa Pharmaceuticals Inc
HAL Allergy BV
Henan Maiyingnuo Pharmaceutical Technology Co Ltd
IACTA Pharmaceuticals Inc
Iltoo Pharma
Inmunotek SL
Invirsa Inc
IVIEW Therapeutics Inc
JW Pharmaceutical Corp
Kedrion SpA
Kissei Pharmaceutical Co Ltd
Marinomed Biotech AG
Microbiotix Inc
Nanomerics Ltd
NanoViricides Inc
Nexeos Bio
Nitto Medic Co Ltd
NTC srl
Ocumension Therapeutics Co Ltd
Okogen Inc
OKYO Pharma Ltd
Plex Pharmaceuticals Inc
Quark Pharmaceuticals Inc
RAPT Therapeutics Inc
Roxall Medizin GmbH
Sacsh Corp
Santen Pharmaceutical Co Ltd
Satellos Bioscience Inc
SIFI SpA
Siolta Therapeutics Inc
Stallergenes Greer Ltd
Stowe Pharmaceuticals Inc
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
Telios Pharma Inc
Union Therapeutics AS
Vanda Pharmaceuticals Inc
Wuhan Yicheng Biotechnology Co Ltd
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Conjunctivitis reports